SEPN SEPTERNA INC

Septerna to Present at TD Cowen 45th Annual Health Care Conference

Septerna to Present at TD Cowen 45th Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder of Septerna, will present at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025, at 10:30 a.m. ET in Boston.

About Septerna

Septerna, Inc. is a biotechnology company pioneering a new era of GPCR drug discovery powered by its proprietary Native Complex Platform™. Its industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of its deep pipeline of oral small molecule product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Septerna was launched by preeminent drug discovery company builders and scientific leaders in the biochemistry, structural biology, and pharmacology of GPCRs. For more information, please visit .

Investor Contact:

Renee Leck

THRUST Strategic Communications



EN
26/02/2025

Underlying

SEPNSEPTERNA INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SEPTERNA INC

 PRESS RELEASE
Free
SEPN SEPTERNA INC

Septerna Highlights Business Progress and Reports First Quarter 2025 F...

Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results Announced Global Collaboration with Novo Nordisk to Develop Oral Small Molecules for Metabolic Diseases with Over $2.2 Billion in Potential Milestone Payments On Track to Select a Next-Generation Oral Small Molecule PTH1R Agonist to Accelerate Toward the Clinic Later in 2025 Expect to Initiate Phase 1 Trial for SEP-631, MRGPRX2 NAM Program for Mast Cell Diseases, in Third Quarter of 2025 Ended First Quarter 2025 with $398.2 Million in Cash, Cash Equivalents and Marketable Securities; Novo Nordisk Colla...

May 15, 2025 1 EN
 PRESS RELEASE
Free
SEPN SEPTERNA INC

Septerna Provides Corporate Overview and Reports Fourth Quarter and Fu...

Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results Preclinical Work Advancing with Plans to Select a Next-Generation Oral Small Molecule PTH1R Agonist to Accelerate Toward the Clinic Later This Year Phase 1 Trial for SEP-631, MRGPRX2 NAM Program for Mast Cell Diseases, Expected to Initiate in 2025 Well-Capitalized with $420.8M Balance Sheet as of YE 2024 to Support Operating Runway into Early 2028 SOUTH SAN FRANCISCO, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-co...

March 27, 2025 1 EN
 PRESS RELEASE
Free
SEPN SEPTERNA INC

Septerna to Present at TD Cowen 45th Annual Health Care Conference

Septerna to Present at TD Cowen 45th Annual Health Care Conference SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder of Septerna, will present at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025, at 10:30 a.m. ET in Boston. About SepternaSepterna, Inc. is a biotechnology company pioneering a new era of GPCR drug discovery powered by its propriet...

February 26, 2025 1 EN
 PRESS RELEASE
Free
SEPN SEPTERNA INC

Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial a...

Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist Trial decision follows unanticipated events of elevated unconjugated bilirubin levels Company advancing multiple next-generation PTH1R agonists with distinct and unrelated chemical structures relative to SEP-786 SOUTH SAN FRANCISCO, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of GPCR drug discovery, today announced its decision to discontinue the Phase 1 single- and m...

February 18, 2025 1 EN
 PRESS RELEASE
Free
SEPN SEPTERNA INC

Septerna Expands Leadership with Appointment of Industry Veteran Gil L...

Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: SEPN), a clinical-stage biotech company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Gil Labrucherie, CFA, J.D., as Chief Financial Officer. Mr. Labrucherie is a seasoned biopharma executive with more than 25 years of senior leadership experience in finance and legal roles for public biopharmaceutical and technology companies. “We are excited to w...

January 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch